Plain language summary: the effects of receiving treatment with migalastat for at least 3 years in people with Fabry disease

Plain Language SummaryWhat is this summary about?Fabry disease is a rare genetic condition where an enzyme, which would normally be present in cells to recycle fatty substances, does not work properly. Fatty substances build up in the lysosome (the cell’s recycling unit), and vital organs become damaged throughout the body.Clinical trials have shown that a treatment called migalastat is effective for treating Fabry disease; however, data on long-term migalastat treatment in real-life usual care are needed. To understand if migalastat treatment in usual care produced similar results to those in clinical trials, researchers looked at 125 people with Fabry disease who received migalastat in usual care for an average of 3.9 years.The researchers used information from the followME Fabry Pathfinders registry, including kidney function, frequency of Fabry-associated complications, and serious health complications. This summary is about the findings from these 125 people.What is the registry looking at?The registry is looking at the health and wellbeing of people with Fabry disease over time who are taking currently available Fabry disease treatments in real-life usual care, focusing on migalastat.What were the results?During migalastat treatment, the rate of kidney function decline in people with Fabry disease was similar to the age-related decline in unaffected people. Most people did not have any specific Fabry-associated complications or any serious health issues during migalastat treatment.What do the results mean?Based on data from real-life usual care, the results of this analysis suggest that migalastat may be an effective long-term treatment for people with Fabry disease who have changes in the Fabry disease gene that are suitable (amenable) to migalastat treatment.How to say (download PDF and double click sound icon to play sound)…Enzyme: EN-zimeGlomerular: glom-AIR-yool-areMigalastat: mi-GAL-a-statPhenotype: FEE-noh-typeThis is an abstract of the Plain Language Summary of Publication article.View the full Plain Language Summary PDF of this article to read the full-textLink to original article here

Authors

Institutions

Publication Details

Journal
Future Rare Diseases
Published
2026-11-19
DOI
https://doi.org/10.1080/23995270.2026.2753743
Primary Topic
Lysosomal Storage Disorders Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Plain language summary: the effects of receiving treatment with migalastat for at least 3 years in people with Fabry disease

Martynas Davidonis, Derralynn A. Hughes, Gere Sunder‐Plassmann, Aaron Flater
Future Rare Diseases
Lysosomal Storage Disorders Research
article

Plain language summary: the effects of receiving treatment with migalastat for at least 3 years in people with Fabry disease

Martynas Davidonis, Derralynn A. Hughes, Gere Sunder‐Plassmann, Aaron Flater
article en

Abstract

Plain Language SummaryWhat is this summary about?Fabry disease is a rare genetic condition where an enzyme, which would normally be present in cells to recycle fatty substances, does not work properly. Fatty substances build up in the lysosome (the cell’s recycling unit), and vital organs become damaged throughout the body.Clinical trials have shown that a treatment called migalastat is effective for treating Fabry disease; however, data on long-term migalastat treatment in real-life usual care are needed. To understand if migalastat treatment in usual care produced similar results to those in clinical trials, researchers looked at 125 people with Fabry disease who received migalastat in usual care for an average of 3.9 years.The researchers used information from the followME Fabry Pathfinders registry, including kidney function, frequency of Fabry-associated complications, and serious health complications. This summary is about the findings from these 125 people.What is the registry looking at?The registry is looking at the health and wellbeing of people with Fabry disease over time who are taking currently available Fabry disease treatments in real-life usual care, focusing on migalastat.What were the results?During migalastat treatment, the rate of kidney function decline in people with Fabry disease was similar to the age-related decline in unaffected people. Most people did not have any specific Fabry-associated complications or any serious health issues during migalastat treatment.What do the results mean?Based on data from real-life usual care, the results of this analysis suggest that migalastat may be an effective long-term treatment for people with Fabry disease who have changes in the Fabry disease gene that are suitable (amenable) to migalastat treatment.How to say (download PDF and double click sound icon to play sound)…Enzyme: EN-zimeGlomerular: glom-AIR-yool-areMigalastat: mi-GAL-a-statPhenotype: FEE-noh-typeThis is an abstract of the Plain Language Summary of Publication article.View the full Plain Language Summary PDF of this article to read the full-textLink to original article here

Future Rare DiseasesVol. 6(1)
Royal Free London NHS Foundation Trust (GB), University College London (GB), Medical University of Vienna (AT)
Lysosomal Storage Disorders Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon